Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Rohrberg KS, Lopez JS, Milhem MM, Blank CU, Reijers I, Thistlethwaite F, Plummer R, Piha-Paul SA, Jänne PA, Shum E, Shaw HM, Debruyne PR, Lao C, Baurain JF, Choe JH, Gort E, Zhao Y, Jerusalem G, Schöffski P, Chen AW, Cohen EA, Mankowski WC, Roshkovan L, Katz SI, Kontos D, Brady LK, Qutaish M, Castro PG, Pencheva N, Bajaj G, Fu Y, Windfeld K, Reiter P, Jure-Kunkel M, Higgs BW, Amiri KI, Ahmadi T, Forssmann U, Ramalingam SS, Vergote I.
Rohrberg KS, et al. Among authors: lopez js.
Cancer Res Commun. 2025 Nov 1;5(11):2066-2078. doi: 10.1158/2767-9764.CRC-25-0359.
Cancer Res Commun. 2025.
PMID: 41166388
Free PMC article.
Clinical Trial.